Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

4results about How to "Binding block" patented technology

A polypeptide specifically binding to coronavirus s protein, encoding gene and application thereof

This invention discloses a polypeptide that specifically binds to the coronavirus S protein, its encoding gene, and its applications, belonging to the field of molecular biology. The polypeptide specifically binding to the coronavirus S protein provided by this invention contains the following amino acid sequence: HFVKTPARWAWG, obtained through screening using phage display technology. The polypeptide provided by this invention can specifically bind to the coronavirus S protein and specifically block the binding of the coronavirus S protein to ACE2, thereby inhibiting coronavirus infection and can be used to prepare anti-coronavirus drugs.
Owner:PRECEDO PHARMA CO LTD

An injection preparation of anti-lilrb4 monoclonal antibody

The present application relates to the field of biological medicine, and specifically provides an anti-LILRB4 monoclonal antibody injection preparation, which comprises an anti-LILRB4 monoclonal antibody, a buffer salt, a protein protective agent, and a surfactant, wherein the pH of the injection preparation is 5.5-6.5. The injection preparation provided by the present application provides a good storage environment for the anti-LILRB4 monoclonal antibody through the synergistic interaction of different contents of the buffer salt, the protein protective agent, and the surfactant, and guarantees the biological activity of the anti-LILRB4 monoclonal antibody. The anti-LILRB4 monoclonal antibody can effectively inhibit the combination of the LILRB4 antigen and its ligand complex, thereby blocking the interaction with the ligand ApoE complex, preventing the activation of the downstream NF-kappa B signal pathway and the release of ARG1, preventing the inhibition of T cell proliferation and the promotion of tissue infiltration, and can be used for treating cancer.
Owner:BEIJING DONGFANG BIOTECH CO LTD

Nanobodies targeting human lllrb2 and uses thereof

Disclosed are an anti-LILRB2 nanobody, a nucleic acid encoding the nanobody, an expression vector comprising the nucleic acid, a pharmaceutical composition comprising the nanobody, and a use for preparing a medicament.
Owner:BEIJING KOHNOOR SCI & TECH CO LTD

Nanobodies targeting human lllrb2 and uses thereof

This invention discloses an anti-LILRB2 nanobody, a nucleic acid encoding the nanobody, an expression vector containing the nucleic acid, a pharmaceutical composition containing the nanobody, and its use in preparing a pharmaceutical product.
Owner:BEIJING KOHNOOR SCI & TECH CO LTD